Antipsychotic drug treatment of schizophrenia in later life: Results from the European cross-sectional AMSP study

To investigate the relationship between patient age and the selection and dosage of antipsychotic drugs (APDs) for treatment of schizophrenia. We describe age effects for multiple individual APDs, thus allowing comparisons between drugs. Prescription data of 32,062 inpatients with schizophrenia from...

Full description

Saved in:
Bibliographic Details
Published inThe world journal of biological psychiatry Vol. 23; no. 5; pp. 374 - 386
Main Authors Zolk, Oliver, Greiner, Timo, Schneider, Michael, Heinze, Martin, Dahling, Volker, Ramin, Tabea, Grohmann, Renate, Bleich, Stefan, Zindler, Tristan, Toto, Sermin, Seifert, Johanna
Format Journal Article
LanguageEnglish
Published England Taylor & Francis 28.05.2022
Subjects
Antipsychotic drugs
drug dosage
elderly
geriatric psychiatry
schizophrenia
drug dosage
Antipsychotic drugs
schizophrenia
geriatric psychiatry
elderly
Online AccessGet full text

Cover

More Information
Summary:To investigate the relationship between patient age and the selection and dosage of antipsychotic drugs (APDs) for treatment of schizophrenia. We describe age effects for multiple individual APDs, thus allowing comparisons between drugs. Prescription data of 32,062 inpatients with schizophrenia from 2000 to 2017 were obtained from the Drug Safety Program in Psychiatry (AMSP) database. APD selection and dosage were related to patient age with sex as an influencing variable. Moreover, a systematic search of current guideline recommendations on APD treatment in patients with schizophrenia aged ≥65 years was performed. Eighty percentof elderly patients (≥65 years) received a second-generation APD, most commonly risperidone. The dosage of APDs increased with age until about age 40 years, then decreased slowly at first and more steeply beyond age 55 years. The influence of age as well as sex on dosage partly differed between the individual drugs. Only one of eight schizophrenia guidelines systematically addressed specific aspects of pharmacotherapy in older adults. In clinical routine, age has a significant impact on selection and dosing of APDs. Information on optimising pharmacotherapy in older adults with schizophrenia from clinical trials is needed. Guidelines should be improved regarding APD therapy specifically for older adults.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:1562-2975
1814-1412
DOI:10.1080/15622975.2021.2011403